Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Board expanded from 10 to 11 directors, adding independent Class II director Robert Scott through the 2028 annual meeting.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 10 to 11 directors, adding independent Class II director Robert Scott through the 2028 annual meeting
- Scott brings former AbbVie Chief Medical Officer and Amgen global development leadership experience, strengthening pharmaceutical development oversight
- Initial option award covers 20,507 shares, vesting in three equal annual installments
- Prorated annual equity award fair valued at approximately $350,000, plus $50,000 board and $5,000 committee cash retainers
- No disclosed related-party transactions, family relationships, or selection arrangements reducing governance concerns
Item 7.01 · Regulation FD Disclosure
- Arcutis appointed Dr. Scott, a leadership change potentially affecting strategy and execution
- Press release dated October 28, 2026, contains the appointment details and should be reviewed for role and transition terms
Item EX-99.1 · Exhibit EX-99.1
- Rob Scott, MD appointed to Arcutis’ board effective October 23, 2026
- Former AbbVie chief medical officer brings experience across approximately 40 new molecular entities and 14 major approvals
- Appointment strengthens oversight of ZORYVE expansion and Arcutis’ novel biologic pipeline
- Scott’s background in dermatology, immunology, clinical development, and regulatory strategy supports pipeline execution
- No compensation terms or committee assignments disclosed in the release
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.